Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study
Links shared publicly online about this topic.
- 740total visits
Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study
View full resource at news-medical.net
Tags: Hypercalcemia Medication, Cancer, Prostate Cancer, Osteoporosis Medication, Prostate, Men's Health, Zometa, Prolia
Most Recently Shared on November 9, 2010 at 7:53 am By:
Osteoporosis News: Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastase... http://bit.ly/d7VhZd
Also Shared By:
Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs
news-medical.net — “Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).” View full resource at news-medical.net
Most Recently Shared on June 7, 2010 at 9:59 am By:
Prostate Cancer: Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs: Amgen... http://bit.ly/aOgmC6
Advertisement
News-Medical.Net
@Lung_Cancer_
Lung Cancer News: Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases... http://bit.ly/d7VhZd
1 year ago...